Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Yahoo! Finance
-- 67% Attack-Free Rate Over 6 Months in Cohorts 2 and 3 -- -- Favorable Safety and Well-Tolerated Profile -- -- Phase 3 Initiation on Track for Q1 2025 -- BOSTON, December 11, 2024 BUSINESS WIRE Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These final results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, and support both every three- (Q3M) and every six-month (Q6M) dosing regimens. The results underscore the potential of navenibart's profile to be the market-leading therapy for HAE. Astria is advancing navenibart to Phase 3 development with
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAEBusiness Wire
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
- Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic DermatitisBusiness Wire
ATXS
Earnings
- 11/13/24 - In-Line
ATXS
Sec Filings
- 12/19/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ATXS's page on the SEC website